Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Cross Below 200-Day Moving Average – Time to Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s share price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.51 and traded as low as $3.45. Cryo-Cell International shares last traded at $3.56, with a volume of 1,803 shares changing hands.

Cryo-Cell International Stock Performance

The company has a market cap of $28.69 million, a PE ratio of -10.79 and a beta of 0.48. The stock’s 50 day moving average price is $3.55 and its 200-day moving average price is $3.51.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $7.68 million during the quarter.

Institutional Investors Weigh In On Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP acquired a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International as of its most recent filing with the SEC. 10.44% of the stock is currently owned by institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.